PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

AHFS Consumer Medication Information [Internet]. Bethesda (MD): American Society of Health-System Pharmacists; 2000-2011.

AHFS Consumer Medication Information.

Oseltamivir(os el tam' i vir)

Last Revision: January 15, 2012.

Why is this medication prescribed?

Oseltamivir is used to treat some types of influenza infection ('flu') in adults and children (older than 1 year of age) who have had symptoms of the flu for no longer than 2 days. This medication is also used to prevent some types of flu in adults and children (older than 1 year of age) when they have spent time with someone who has the flu or when there is a flu outbreak. Oseltamivir is in a class of medications called neuraminidase inhibitors. It works by stopping the spread of the flu virus in the body. Oseltamivir helps shorten the time you have flu symptoms such as a stuffy or runny nose, sore throat, cough, muscle or joint aches, tiredness, headache, fever, and chills. Oseltamivir will not prevent bacterial infections, which may occur as a complication of the flu.

How should this medicine be used?

Oseltamivir comes as a capsule and a suspension (liquid) to take by mouth. When oseltamivir is used to treat flu symptoms, it is usually taken two times a day (morning and evening) for 5 days. When oseltamivir is used to prevent flu, it is usually taken once a day for at least 10 days, or for up to 6 weeks during a community flu outbreak. Oseltamivir may be taken with or without food, but you may lessen the chance of getting an upset stomach by taking oseltamivir with food or milk. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part that you do not understand. Take oseltamivir exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Sometimes doses of oseltamivir oral suspension are measured in milliliters (mL) and sometimes they are measured in milligrams (mg). This depends on the age of the person being treated and on whether the commercial suspension or a suspension that has been prepared by a pharmacist is being used. It is important to know whether your or your child's dose should be measured in mL or mg and to use a measuring device that will measure the dose in the proper units. If you are using a suspension that was prepared by a pharmacist, the dose should be measured in mL. If you are using the commercial suspension to treat a person older than one year of age, the dose should be measured in mg. If you are using either product to treat a child under one year of age, the dose should be measured in mL. Before taking oseltamivir oral suspension, check to be sure that the instructions on the prescription label are given in the proper units as described above and that the measuring device that was provided is marked in the proper units. If you think that the directions on your prescription label are incorrect, that the measuring device you received is marked with the wrong units, or you have any questions about how to measure the medication, call your doctor or pharmacist. Never use a household teaspoon to measure doses of oseltamivir oral suspension.

If you are giving the commercial suspension to a child over one year of age, follow these steps to measure the dose using the syringe provided:

  1. Shake the suspension well (for about 5 seconds) before each use to mix the medication evenly.

  2. Open the bottle by pushing down on the cap and turning the cap at the same time.

  3. Push the plunger of the measuring device completely down to the tip.

  4. Insert the tip of the measuring device firmly into the opening on the top of the bottle.

  5. Turn the bottle (with the measuring device attached) upside down.

  6. Pull back on the plunger slowly until the amount of suspension prescribed by your doctor fills the measuring device to the appropriate marking (in milligrams [mg]). Some larger doses may need to be measured using the measuring device twice. If you are not sure how to correctly measure the dose your doctor has prescribed, ask your doctor or pharmacist.

  7. Turn the bottle (with the measuring device attached) right-side up and slowly remove the measuring device.

  8. Take oseltamivir directly into your mouth from the measuring device; do not mix with any other liquids.

  9. Replace the cap on the bottle and close tightly.

  10. Remove the plunger from the rest of the measuring device and rinse both parts under running tap water. Allow the parts to air dry before putting back together for the next use.

Call your doctor or pharmacist to find out how you should measure a dose of oseltamivir suspension if you do not have the measuring device that came with this medication.

If you have difficulty swallowing capsules, your doctor may tell you to open the capsule and mix the contents with a sweetened liquid. To prepare doses of oseltamivir for people who cannot swallow the capsules:

  1. Hold the capsule over a small bowl and carefully pull open the capsule and empty all of the powder from the capsule into the bowl. If your doctor has instructed you to take more than one capsule for your dose, then open the correct number of capsules into the bowl.

  2. Add a small amount of sweetened liquid, such as regular or sugar-free chocolate syrup, to the powder.

  3. Stir the mixture.

  4. Swallow the entire contents of this mixture right away.

Continue to take oseltamivir until you finish the prescription, even if you start to feel better. Do not stop taking oseltamivir without talking to your doctor. If you stop taking oseltamivir too soon or skip doses, your infection may not be fully treated, or you may not be protected from the flu.

If you feel worse or develop new symptoms while taking oseltamivir, or if your flu symptoms do not start to get better, call your doctor.

Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.

Other uses for this medicine

Oseltamivir may be used to treat and prevent infections from avian (bird) influenza (a virus that usually infects birds but can also cause serious illness in humans). Oseltamivir also may be used to treat and prevent infections from from influenza A (H1N1).

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking oseltamivir,

  • tell your doctor and pharmacist if you are allergic to oseltamivir or any other medications.

  • tell your doctor what prescription and nonprescription medications, vitamins, nutritional supplements and herbal products you are taking or plan to take. Be sure to mention any of the following: medications that affect the immune system such as azathioprine (Imuran); cyclosporine (Neoral, Sandimmune); cancer chemotherapy medications; methotrexate (Rheumatrex); sirolimus (Rapamune); oral steroids such as dexamethasone (Decadron, Dexone), methylprednisolone (Medrol), and prednisone (Deltasone); or tacrolimus (Prograf). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have ever taken oseltamivir to treat or prevent the flu.

  • tell your doctor if you have any disease or condition that affects your immune system such as human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) or if you have heart, liver, lung, or kidney disease.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking oseltamivir, call your doctor.

  • you should know that people, especially children and teenagers, who have the flu may become confused, agitated, or anxious, and may behave strangely, have seizures or hallucinate (see things or hear voices that do not exist), or harm or kill themselves. You or your child may develop these symptoms whether or not you or your child uses oseltamivir, and the symptoms may begin shortly after starting treatment if you do use the medication. If your child has the flu, you should watch his or her behavior very carefully and call the doctor right away if he or she becomes confused or behaves abnormally. If you have the flu, you, your family, or your caregiver should call the doctor right away if you become confused, behave abnormally, or think about harming yourself. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.

  • ask your doctor if you should receive a flu vaccination each year. Oseltamivir does not take the place of a yearly flu vaccine. If you received or plan to receive the intranasal flu vaccine (FluMist; flu vaccine that is sprayed into the nose), you should tell your doctor before taking oseltamivir. Oseltamivir may make the intranasal flu vaccine less effective if it is taken up to 2 weeks after or up to 48 hours before the intranasal flu vaccine is given.

  • if you have fructose intolerance (an inherited condition in which the body lacks the protein needed to break down fructose, a fruit sugar, such as sorbitol), you should know that the oseltamivir suspension is sweetened with sorbitol. A 75 mg dose of oseltamivir suspension contains 2 grams of sorbitol, which is likely above the recommended maximum daily amount of sorbitol for someone with this condition. Tell your doctor if you have fructose intolerance.

What should I do if I forget a dose?

If you forget to take a dose, take it as soon as you remember it. If it is no longer than 2 hours before your next scheduled dose, skip the missed dose and continue your regular dosing schedule. If you miss several doses, call your doctor for directions. Do not take a double dose to make up for a missed one.

What side effects can this medication cause?

Oseltamivir may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • nausea

  • vomiting

  • stomach pain

  • diarrhea

  • headache

Some side effects can be serious. If you experience any of these symptoms or those mentioned in the SPECIAL PRECAUTIONS section, call your doctor immediately:

  • rash, hives, or blisters on the skin

  • itching

  • swelling of the face or tongue

  • difficulty breathing or swallowing

  • hoarseness

  • changes in behavior

If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online [at http://www.fda.gov/Safety/MedWatch] or by phone [1-800-332-1088].

What storage conditions are needed for this medicine?

Keep this medication in the container it came in and out of reach of children. Store the capsules at room temperature and away from excess heat and moisture (not in the bathroom). Keep the suspension in the refrigerator. Do not freeze oseltamivir suspension. Throw away any unused suspension after 10 days. Throw away any medication that is outdated or no longer needed. Talk to your pharmacist about the proper disposal of your medication.

In case of emergency/overdose

In case of overdose, call your local poison control center at 1-800-222-1222. If the victim has collapsed or is not breathing, call local emergency services at 911.

Symptoms of overdose may include:

  • nausea

  • vomiting

What other information should I know?

Oseltamivir will not stop you from giving the flu to others. You should wash your hands frequently, and avoid practices such as sharing cups and utensils that can spread the virus to others.

Do not let anyone else take your medication. Your prescription is probably not refillable. If you still have symptoms of the flu after you finish taking oseltamivir, call your doctor.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. represents that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. makes no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS® Consumer Medication Information. © Copyright, 2011. The American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.

The following brand names are from RxNorm, a standardized nomenclature for clinical drugs produced by the National Library of Medicine:

Brand names

  • Tamiflu

What works?

  • A review of unpublished regulatory information from trials of neuraminidase inhibitors (Tamiflu ‐ oseltamivir and Relenza ‐ zanamivir) for influenza A review of unpublished regulatory information from trials of neuraminidase inhibitors (Tamiflu ‐ oseltamivir and Relenza ‐ zanamivir) for influenza
    We decided to update and amalgamate our reviews on the antiviral drugs zanamivir and oseltamivir for influenza on the basis of the manufacturers' reports to regulators (called clinical study reports) and regulators' comments (which we called regulatory information). Clinical study reports are extensive documents with exhaustive details of the trial protocol, methods and results. In view of the unresolved discrepancies in the data presented in published trial reports and of the substantial risk publication bias in this area, we elected not to use data from journal articles. Availability of documents generated by national and regional regulatory bodies during licensing processes in the UK, USA, continental Europe and Japan, partial trial reports from the manufacturers of oseltamivir and from the European regulator European Medicines Agency (EMA), enabled us to verify information from the trials. The authors have been unable to obtain the full set of clinical study reports or obtain verification of data from the manufacturer of oseltamivir (Roche) despite five requests between June 2010 and February 2011. No substantial comments were made by Roche on the protocol of our Cochrane Review which has been publicly available since December 2010. Based on our assessments of the documents we could obtain, we came to the conclusion that there were substantial problems with the design, conduct and availability of information from many of the trials. Due to these concerns we decided not to proceed with a meta‐analysis of all the oseltamivir data as we had intended. Instead we carried out analyses of effects on symptoms (shortens them by 21 hours or so) and hospitalisations (no evidence of effect) of people with influenza‐like illness ('flu') on data from all the people enrolled in treatment trials of oseltamivir. Other outcomes could not be assessed due to unavailability of data for all the people enrolled in treatment trials of oseltamivir.  Our independent analysis concurs with the conservative conclusions regarding the effects of both drugs by the US Food and Drug Administration (FDA). The FDA only allowed claims of effectiveness of both drugs for the prevention and treatment of symptoms of influenza and not on other effects (such as interruption of person‐to‐person spread of the influenza virus or prevention of pneumonia). There is evidence to suggest that both drugs are associated with harms (oseltamivir: nausea, vomiting; zanamivir: probably asthma). The FDA described the overall performance of both drugs as "modest". We expect full clinical study reports containing study protocol, reporting analysis plan, statistical analysis plan and individual patient data to clarify outstanding issues. These full clinical study reports are at present unavailable to us.
See all (8)...

Learn about...

  • Tips for reading the news Tips for reading the news
    Don’t automatically believe the headlines. Learn how to figure out which articles you’re going to believe and which you’re not.

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...